124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trialMafalda Oliveira, Aleix Prat, F.J. Salvador Bofill et al.|ESMO Open|2023Cited by 8
155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trialMafalda Oliveira, Aleix Prat, Tomás Pascual et al.|ESMO Open|2023Cited by 6
3MO HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): A correlative analysis from SOLTI-TOT-HER3 trialFara Brasó‐Maristany, Aleix Prat, Mafalda Oliveira et al.|ESMO Open|2023Cited by 0